ChemoCentryx, Inc. Form 4 June 27, 2013

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

0.5

January 31, Expires: 2005

**OMB APPROVAL** 

Estimated average burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Bekker Petrus		2. Issuer Name <b>and</b> Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer			
		ChemoCentryx, Inc. [CCXI]	(Check all applicable)			
(Last) (First) (	Middle)	3. Date of Earliest Transaction				
		(Month/Day/Year)	Director 10% Owner			
C/O CHEMOCENTRYX, IN MAUDE AVENUE	NC., 850	06/25/2013	X Officer (give title Other (specify below) SVP of Medical & Clinical			
(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check			
		Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person			
MOUNTAIN VIEW CA 94043			Form filed by More than One Reporting			

Person

#### **MOUNTAIN VIEW, CA 94043**

(City)	(State) (Z	Zip) Table	I - Non-De	erivative S	Securi	ties Ac	quired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed 3.		4. Securities onAcquired (A) or Disposed of (D)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
~			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	06/25/2013		M	1,867	A	\$ 6	55,461	D	
Common Stock	06/25/2013		S(1)	1,867	D	\$ 14	53,594	D	
Common Stock	06/26/2013		M	117	A	\$6	53,711	D	
Common Stock	06/26/2013		S(1)	117	D	\$ 14	53,594	D	
Common Stock	06/27/2013		M	3,016	A	\$6	56,610	D	

### Edgar Filing: ChemoCentryx, Inc. - Form 4

Common Stock

06/27/2013

 $S^{(1)}$ 3,016 D

\$ 14 53,594

D

(9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Secu Acqu (A) o Disp (D)	rities aired or osed of r. 3, 4,	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun or Numbe of Shares
Employee Stock Option (right to buy)	\$ 6	06/25/2013		M		1,867	07/28/2009(2)	07/28/2019	Common Stock	1,867
Employee Stock Option (right to buy)	\$ 6	06/26/2013		M		117	07/28/2009(2)	07/28/2019	Common Stock	117
Employee Stock Option (right to buy)	\$ 6	06/27/2013		M		3,016	07/28/2009(2)	07/28/2019	Common Stock	3,016

# **Reporting Owners**

Relationships Reporting Owner Name / Address

> Officer Other Director 10% Owner

Bekker Petrus SVP of Medical & Clinical

C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE

2 Reporting Owners

**MOUNTAIN VIEW, CA 94043** 

## **Signatures**

/s/ Christopher Geissinger, as Attorney-in-Fact

06/27/2013

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- (2) As of June 25, 2013 and prior to this transaction, the option fully vested.
- (3) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3